FDA and OpenAI Explore AI Integration for Accelerating Drug Evaluations

8 Sources

The FDA is in talks with OpenAI to implement AI in drug evaluation processes, aiming to speed up approvals. This move raises questions about data security and the reliability of AI in critical healthcare decisions.

News article

FDA and OpenAI Collaborate on AI-Assisted Drug Evaluations

The U.S. Food and Drug Administration (FDA) is reportedly in discussions with OpenAI to integrate artificial intelligence into its drug evaluation processes. This collaboration aims to accelerate the notoriously lengthy drug approval timeline, which can often exceed a decade 12.

Project cderGPT and Key Players

At the center of these talks is a project called cderGPT, likely referring to an AI tool for the Center for Drug Evaluation and Research (CDER), which regulates over-the-counter and prescription drugs in the U.S. 12. The discussions have involved a small team from OpenAI, FDA officials, and associates from Elon Musk's Department of Government Efficiency 2.

Jeremy Walsh, the FDA's first-ever AI officer, has been leading these discussions. Additionally, Peter Bowman-Davis, an undergraduate student on leave from Yale serving as the acting chief AI officer at the Department of Health and Human Services, has been involved in conversations about the FDA's AI ambitions 2.

Potential Benefits and Timeline

FDA Commissioner Marty Makary has expressed enthusiasm for modernizing the drug approval process with AI, stating that the agency has already completed its first AI-assisted scientific review for a product 2. The FDA aims to achieve full AI integration across all its centers by June 30, an ambitious timeline that has raised some concerns 5.

Concerns and Challenges

While the integration of AI in drug evaluation processes holds promise, it also raises several questions:

  1. Data Security: There are concerns about securing the vast amount of proprietary company data involved in the drug approval process 4.

  2. AI Reliability: Given the critical nature of drug approvals, the potential for AI hallucinations and errors is a significant concern 5.

  3. Training Data: Questions remain about which models are being used to train the AI and what inputs are being provided for specialized fine-tuning 4.

  4. Regulatory Framework: There is a need for policy guidance on acceptable AI model performance and the types of data used for training 2.

Broader Context of AI in Government

The FDA's AI initiative is part of a larger trend of AI adoption in federal agencies during the Trump administration. This includes OpenAI's ChatGPT Gov, designed to process sensitive government information, and efforts to use AI in other departments such as the General Services Administration and Social Security 5.

Expert Opinions

Rafael Rosengarten, CEO of Genialis and a board member of the Alliance for AI in Healthcare, supports automating certain tasks in the drug review process but emphasizes the need for careful implementation 2. Former FDA Commissioner Robert Califf noted that the agency has been experimenting with AI for several years and sees broader opportunities beyond final reviews 25.

As the FDA moves forward with its AI integration plans, balancing innovation with potential risks will be crucial. The outcome of this initiative could set a precedent for AI use in critical government functions and healthcare decision-making processes.

Explore today's top stories

Netflix Pioneers Use of Generative AI in Original Content Production

Netflix has incorporated generative AI technology in its original series "El Eternauta," marking a significant shift in content production methods for the streaming giant.

TechCrunch logoCNET logoThe Verge logo

23 Sources

Technology

13 hrs ago

Netflix Pioneers Use of Generative AI in Original Content

Meta Refuses to Sign EU's AI Code of Practice, Citing Overreach and Innovation Concerns

Meta declines to sign the European Union's voluntary AI code of practice, calling it an overreach that could stifle innovation and economic growth in Europe. The decision highlights growing tensions between tech giants and EU regulators over AI governance.

TechCrunch logoReuters logoengadget logo

13 Sources

Policy and Regulation

13 hrs ago

Meta Refuses to Sign EU's AI Code of Practice, Citing

OpenAI Advisory Board Recommends Continued Nonprofit Oversight for AI Development

An advisory board convened by OpenAI recommends that the company should continue to be controlled by a nonprofit, emphasizing the need for democratic participation in AI development and governance.

AP NEWS logoTech Xplore logoThe Seattle Times logo

6 Sources

Policy and Regulation

13 hrs ago

OpenAI Advisory Board Recommends Continued Nonprofit

Perplexity AI Surges in India, Challenging ChatGPT's Dominance

Perplexity AI partners with Airtel to offer free Pro subscriptions, leading to a significant increase in downloads and user base in India, potentially reshaping the AI search landscape.

TechCrunch logoAnalytics India Magazine logoEconomic Times logo

5 Sources

Technology

13 hrs ago

Perplexity AI Surges in India, Challenging ChatGPT's

Perplexity AI Secures $100 Million Funding, Reaching $18 Billion Valuation

Perplexity AI, an AI-powered search engine startup, has raised $100 million in a new funding round, valuing the company at $18 billion. This development highlights the growing investor interest in AI startups and Perplexity's potential to challenge Google's dominance in internet search.

Bloomberg Business logoAnalytics India Magazine logoEconomic Times logo

4 Sources

Startups

13 hrs ago

Perplexity AI Secures $100 Million Funding, Reaching $18
TheOutpost.ai

Your Daily Dose of Curated AI News

Don’t drown in AI news. We cut through the noise - filtering, ranking and summarizing the most important AI news, breakthroughs and research daily. Spend less time searching for the latest in AI and get straight to action.

© 2025 Triveous Technologies Private Limited
Instagram logo
LinkedIn logo